908 Devices Inc. (NASDAQ: MASS) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.00 | Insider Own | 20.31% | Shs Outstand | 41.03M | Perf Week | 12.18% |
| Market Cap | 328.63M | Forward P/E | - | EPS next Y | -0.32 | Insider Trans | -7.72% | Shs Float | 30.79M | Perf Month | -9.80% |
| Enterprise Value | 265.53M | PEG | 0.00 | EPS next Q | - | Inst Own | - | Short Float | 10.51% | Perf Quarter | 17.28% |
| Income | -39.99M | P/S | 5.69 | EPS this Y | 60.00% | Inst Trans | - | Short Ratio | 11.28 | Perf Half Y | 26.14% |
| Sales | 57.80M | P/B | 2.20 | EPS next Y | 21.00% | ROA | -19.23% | Short Interest | 3.23M | Perf YTD | 52.57% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -25.50% | 52W High | 9.82 -14.24% | Perf Year | 17.62% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -20.50% | 52W Low | 5.29 59.24% | Perf 3Y | 14.92% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 6.01% 15.71% | Gross Margin | 49.00% | Volatility | 6.63% 5.89% | Perf 5Y | -75.41% |
| Dividend TTM | - | EV/Sales | 4.59 | EPS Y/Y TTM | 52.83% | Oper. Margin | -52.50% | ATR (14) | 0.47 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.25 | Sales Y/Y TTM | -5.00% | Profit Margin | -62.10% | RSI (14) | 54.91 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.58 | EPS Q/Q | 0.00% | SMA20 | 4.84% | Beta | 0.63 | Target Price | - |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | 8.33% | SMA50 | -1.10% | Rel Volume | 1.11 | Prev Close | 8.01 |
| Employees | 172 | LT Debt/Eq | 0.04 | Earnings | Aug 11 | SMA200 | 14.64% | Avg Volume | 302.48K | Price | 8.42 |
| IPO Date | Dec 18, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -57.14% 1.67% | Net Debt/EBITDA | 2.37 | Volume | 335,294 | Change | 5.12% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform | |
| Nov-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 57 | 56 | 60 | 50 | 47 | 42 | 27 | 18 | 22 | |
| Cost of Goods Sold Incl. D&A | 30 | 29 | 30 | 25 | 21 | 19 | 12 | 10 | 10 | |
| Gross Profit | 28 | 27 | 30 | 25 | 26 | 23 | 15 | 8 | 12 | |
| Selling, General and Administrative Excl. Other | 28 | 37 | 0 | 0 | 44 | 32 | 0 | 0 | 9 | |
| Research and Development | 13 | 14 | 25 | 22 | 18 | 13 | 8 | 9 | 10 | |
| Other Operating Expense | 18 | 0 | 82 | 46 | -1 | 0 | 13 | 11 | 0 | |
| Operating Income | -31 | -24 | -77 | -43 | -35 | -22 | -6 | -12 | -6 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -5 | -9 | 4 | 6 | 2 | 0 | -6 | 0 | 0 | |
| Net Income Before Taxes | -36 | -33 | -72 | -37 | -34 | -22 | -13 | -13 | -8 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -36 | -37 | -72 | -36 | -34 | -22 | -13 | -13 | -8 | |
| Net Income From Continuing Operations | -36 | -33 | -72 | -36 | -34 | -22 | -13 | -13 | -8 | |
| Net Income | -36 | -37 | -72 | -36 | -34 | -22 | -13 | -13 | -8 | |
| EPS (Recurring) | -0.98 | 0.54 | -2.12 | -1.13 | -1.07 | -0.79 | -2.35 | -2.02 | -0.93 | |
| EPS (Basic, Before Extraordinaries) | -0.98 | 0.54 | -2.12 | -1.13 | -1.07 | -0.79 | -2.35 | -2.02 | -0.93 | |
| EPS (Diluted) | -1.00 | 0.54 | -2.12 | -1.13 | -1.07 | -0.79 | -2.35 | -2.02 | -0.93 | |
| EBITDA | -27 | -29 | -44 | -40 | -32 | -21 | -5 | -11 | -5 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 9.72 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.47 | 3.38 | 1.25 | 7.18 | 5.03 | 17.25 | 10.55 | — | — | |
| Gross Margin | 49.12 | 48.21 | 50.00 | 50.00 | 55.32 | 54.76 | 55.56 | 44.44 | 54.55 | |
| Operating Margin | -54.39 | -42.86 | -128.33 | -86.00 | -74.47 | -52.38 | -22.22 | -66.67 | -27.27 | |
| Net Margin | -63.16 | -66.07 | -120.00 | -72.00 | -72.34 | -52.38 | -48.15 | -72.22 | -36.36 | |
| Shares Outstanding | 37 | 36 | 34 | 32 | 31 | 28 | 5 | 8 | 8 | |
| Market Capitalization | 312 | 189 | 75 | 359 | 236 | 724 | 285 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brown Christopher D. | Director | Jul 02 '26 | Sale | 9.02 | 2,200 | 19,844 | 843,359 | Jul 07 |
| Knopp Kevin J. | President and CEO | Jul 02 '26 | Sale | 9.07 | 222 | 2,014 | 732,603 | Jul 07 |
| Brown Christopher D. | Director | Jun 30 '26 | Sale | 8.84 | 20,000 | 176,800 | 845,559 | Jul 02 |
| Knopp Kevin J. | President and CEO | Jun 26 '26 | Sale | 9.09 | 2,798 | 25,434 | 732,825 | Jun 30 |
| Knopp Kevin J. | President and CEO | Jun 25 '26 | Sale | 9.10 | 16,388 | 149,131 | 735,623 | Jun 25 |
| Leonhart Michele M. | Director | Jun 25 '26 | Option Exercise | 0.00 | 6,486 | 0 | 27,054 | Jun 25 |
| Knopp Kevin J. | President and CEO | Jun 24 '26 | Sale | 9.14 | 40,535 | 370,490 | 752,011 | Jun 25 |
| Knopp Kevin J. | President and CEO | Jun 23 '26 | Sale | 9.06 | 3,422 | 31,003 | 792,546 | Jun 25 |
| Brown Christopher D. | Director | Jun 23 '26 | Sale | 9.04 | 9,900 | 89,496 | 865,559 | Jun 25 |
| AWM Investment Company, Inc. | 10% Owner | Jun 23 '26 | Sale | 9.00 | 3,050 | 27,463 | 4,879,773 | Jun 24 |
| AWM Investment Company, Inc. | 10% Owner | Jun 22 '26 | Sale | 8.99 | 4,668 | 41,965 | 4,882,823 | Jun 24 |
| CRANDELL KEITH | Director | Jun 10 '26 | Option Exercise | 0.00 | 14,083 | 0 | 39,374 | Jun 12 |
| Leonhart Michele M. | Director | Jun 10 '26 | Option Exercise | 0.00 | 14,083 | 0 | 20,568 | Jun 12 |
| HRUSOVSKY E KEVIN | Director | Jun 10 '26 | Option Exercise | 0.00 | 14,083 | 0 | 165,390 | Jun 12 |
| Spoto Mark | Director | Jun 10 '26 | Option Exercise | 0.00 | 14,083 | 0 | 89,346 | Jun 12 |